{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
An observational survey study to analyze management of Chronic obstructive pulmonary disease (COPD)

(To be filled only by physician)

  1. As per your clinical practice, what is the approximate number of patients newly diagnosed with Chronic obstructive pulmonary disease (COPD) every month? *

  2. What are the common complaints or signs-symptoms observed in patients with COPD? (Please tick all the applicable options) *

  3. What is the approximate percentage of patients having comorbidities in patients with COPD, as per observation in your practice? (Please fill the approximate percentage) *
    4. Percentage (%)

    Percentage of patients having comorbidities in patients with COPD

  4. What are the common comorbidities observed in patients with COPD? (Please tick all the applicable options) *

  5. What is the approximate break up of patients in percentage based on severity of COPD, as observed in your practice? *
    6. Percentage

    GOLD 2023 grade 1

    GOLD 2023 grade 2

    GOLD 2023 grade 3

    GOLD 2023 grade 4

    Total

    100%

  6. What is the approximate break up of patients on the below specific therapies based on severity of GOLD 2023 Group A stage of COPD, as observed in your practice? *
    7. Percentage

    Long Acting Beta-Agonists (LABAs)

    Long acting muscarinic antagonists (LAMA)

    Any other

    Total

    100%

  7. What is the approximate break up of patients on the below specific therapies based on severity of GOLD 2023 Group B stage of COPD, as observed in your practice? *
    8. Percentage

    Long Acting Beta-Agonists (LABAs)

    Long acting muscarinic antagonists (LAMA)

    Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Any other

    Total

    100%

  8. What is the approximate break up of patients on the below specific therapies based on severity of GOLD 2023 Group E stage of COPD, as observed in your practice? *
    9. Percentage

    Long Acting Beta-Agonists (LABAs)

    Long acting muscarinic antagonists (LAMA)

    Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Inhaled corticosteroids (ICS)+ Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Any other

    Total

    100%

  9. What is the approximate percentage of patients with COPD requiring Inhaled corticosteroids (ICS)+ Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations per month, as per your practice? *

  10. What is the approximate percentage of patients with COPD requiring Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations per month, as per your practice? *

  11. What is the approximate percentage of patients with COPD requiring Acebrophylline per month, as per your practice? *

  12. How would you rate the role of Acebrophylline for patients with COPD in addition to below mentioned medications? *
    13. Parameter Strongly recommended Recommended Neutral

    Inhaled corticosteroids (ICS) + Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Long-Acting Beta-Agonists (LABA)

    Long acting muscarinic antagonists (LAMA) combinations

  13. How would you rate the role of Acebrophylline for patients with COPD as per the disease severity? *
    14. Parameter Strongly recommended Recommended Neutral

    GOLD 2023 Group A stage of COPD

    GOLD 2023 Group B stage of COPD

    GOLD 2023 Group E stage of COPD

  14. Which Long-Acting Beta-Agonists (LABAs) agent do you prefer the most in your clinical practice? *

  15. What criteria’s do you use for choosing a Long-Acting Beta-Agonists (LABAs) agent in your patient with COPD? *

  16. Do you prefer Acebrophylline in patients with exacerbations, as per your clinical practice? *

  17. Kindly share the approximate break up of usage of Long Acting Beta-Agonists (LABAs) + Long acting muscarinic antagonists (LAMA) combination as per patient profile in patients with COPD, in your clinical practice? *
    18. Condition Percentage

    Newly diagnosed

    Treatment experienced

    Total percentage

    100%

  18. Kindly share the approximate break up of usage of Inhaled corticosteroids (ICS) + Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations as per patient profile in patients with COPD, in your clinical practice? *
    19. Condition Percentage

    Newly diagnosed

    Treatment experienced

    Total percentage

    100%

  19. Which of the following below parameters do you consider for selecting the Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations in patients with COPD, as per your practice? (Tick all applicable) *

  20. How would you rate the below medications for COPD in terms of FEV1 Improvement from baseline? *
    21. Parameter Strongly recommended Recommended Neutral

    Inhaled corticosteroids (ICS) + Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Long-Acting Beta-Agonists (LABA)

    Long acting muscarinic antagonists (LAMA) combinations

    Acebrophylline

  21. How would you rate the below medications for COPD in terms of Improvement in annual moderate /severe exacerbation rates from baseline? *
    22. Parameter Strongly recommended Recommended Neutral

    Inhaled corticosteroids (ICS) + Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations

    Long-Acting Beta-Agonists (LABA)

    Long acting muscarinic antagonists (LAMA) combinations

    Acebrophylline

  22. Kindly share the approximate break up of usage of Long-Acting Beta-Agonists (LABA) + Long acting muscarinic antagonists (LAMA) combinations as per disease condition in patients with COPD, as per your clinical practice? *
    23. Stage Percentage

    GOLD 2023 Group A stage of COPD

    GOLD 2023 Group B stage of COPD

    GOLD 2023 Group E stage of COPD

    Total

    100%

  23. How would you rate the below ICS + LABA combinations in terms of efficacy in patients with COPD, as per observations in your clinical practice? *
    24. ICS + LABA Strongly recommended Recommended Neutral

    Budesonide-Formoterol

    Fluticasone Propionate-Salmeterol

    Fluticasone Propionate -Formoterol

    Fluticasone Furoate-Vilanterol

  24. What are the criteria for selecting the specific LABA + LAMA combinations as per observations in your practice? (Kindly tick all applicable) *

  25. Which is your preferred ICS + LABA combinations in terms of efficacy & safety in COPD patients with below comorbid conditions/ specific patient profiles? *
    26. ICS + LABA Cardio-vascular co-morbidity Asthma Renal impairment

    Budesonide-Formoterol

    Fluticasone Propionate-Salmeterol

    Fluticasone Propionate -Formoterol

    Fluticasone Furoate-Vilanterol

  26. How would you rate the below ICS + LABA combinations in terms of safety in patients with COPD, as per observations in your clinical practice? *
    27. ICS + LABA Strongly recommended Recommended Neutral

    Budesonide-Formoterol

    Fluticasone Propionate-Salmeterol

    Fluticasone Propionate -Formoterol

    Fluticasone Furoate-Vilanterol

  27. What is the approximate percentage of patients with COPD have cardio-vascular co-morbidity, as observed in your practice? *

  28. Approximately for how long acebrophylline is given in your patients with COPD? *

  29. Do you observe any challenges in terms of adherence with acebrophylline in patients with COPD, as per observations in your clinical practice? (Tick the appropriate feedback) *